On 18 Nov 2025, Sequent Scientific's stock price demonstrated strong upward movement, touching its highest level in the past year at Rs.249.15. The stock's day change registered at 7.2%, substantially outperforming the sector by 7.62%. This performance comes amid a broader market environment where the Sensex opened positively but later declined by 287.57 points, trading at 84,754.80, down 0.23% for the day.
Sequent Scientific's price action today is supported by its position above key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a sustained upward trend across multiple timeframes. The stock has also recorded gains for two consecutive days, accumulating returns of 8.53% over this period.
Comparatively, the Sensex remains close to its 52-week high, currently 0.63% below the peak of 85,290.06. The index trades above its 50-day moving average, which itself is positioned above the 200-day moving average, suggesting a generally bullish market backdrop despite today's intraday dip.
Momentum just kicked in! This small-cap from the Pharmaceuticals & Biotechnology sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- Fresh momentum detected
- Explosive short-term signals
- Early wave positioning
Examining Sequent Scientific's performance over various time horizons highlights its relative strength. The stock's one-day gain of 7.11% contrasts with the Sensex's decline of 0.23%. Over the past week, Sequent Scientific has returned 8.35%, while the Sensex recorded a 1.05% increase. The one-month performance shows a 22.10% rise for the stock against the Sensex's 0.95%.
Longer-term data further emphasises the stock's trajectory. Over three months, Sequent Scientific's returns stand at 41.12%, significantly outpacing the Sensex's 4.28%. The one-year performance shows a 31.18% return for the stock compared to the Sensex's 9.59%. Year-to-date, the stock has gained 40.80%, while the Sensex has advanced 8.46%.
Over a three-year span, Sequent Scientific has delivered a cumulative return of 168.91%, markedly higher than the Sensex's 37.44%. However, over five years, the stock's 62.12% return trails the Sensex's 91.84%. The ten-year performance shows Sequent Scientific at 37.40%, compared with the Sensex's 232.59%, reflecting differing growth trajectories over extended periods.
Why settle for Sequent Scientific ? SwitchER evaluates this Pharmaceuticals & Biotechnology small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- Comprehensive evaluation done
- Superior opportunities identified
- Smart switching enabled
Sequent Scientific's Mojo Score currently stands at 57.0, with a Mojo Grade of Hold as of 02 Sep 2025, reflecting an adjustment in its evaluation from a previous Sell grade. The stock's market capitalisation grade is 3, indicating its classification within the small-cap segment of the Pharmaceuticals & Biotechnology sector.
Today's trading session saw Sequent Scientific's stock outperform the broader market and sector indices, with a clear surge to its intraday peak. The stock's ability to maintain levels above all major moving averages suggests continued interest in the current price range, supported by recent positive momentum signals.
While the Sensex experienced a decline after a positive start, Sequent Scientific's performance diverged positively, highlighting its relative strength within the Pharmaceuticals & Biotechnology sector. This divergence is notable given the sector's overall market dynamics and the stock's recent consecutive gains.
Investors monitoring the stock will note the significance of the new 52-week high of Rs.249.15, which represents a key technical milestone. The stock's performance today, combined with its recent upward trend, underscores its current market positioning amid a fluctuating broader market environment.
Overall, Sequent Scientific's strong intraday performance today, marked by a 7.2% rise and a new 52-week high, reflects a notable episode of trading activity within the Pharmaceuticals & Biotechnology sector. The stock's relative outperformance against the Sensex and sector benchmarks provides a clear data point for market participants analysing current market movements.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
